Table 3.
Description of all found associations between chlordane compounds and diabetes-related features.
| Publication characteristics | Chlordane compound | ||||||
|---|---|---|---|---|---|---|---|
| Oxychlordane | Trans-nonachlor | Heptachlor | Chlordane | ||||
| References | Sex. Age group subjects | Diabetes | Exposure Contrast # | Estimate (95% CI) | Estimate (95% CI) | Estimate (95% CI) | Estimate (95% CI) |
| Lee et al.25 | ♂♀ (≥ 20) |
FBG or NFBG or Self-reported |
≥ 90th vs. BDL |
OR = 6.50 (1.99; 21.26) |
OR = 11.8 (4.4; 31.3) |
||
| Cox et al.33 | ♂♀ (20–74) | Self-reported | > 143.75 vs- detectable limit (ppb) |
OR = 2.20 (0.37; 13.15) |
OR = 1.50 (0.43; 5.25) |
||
| Lee et al.26 | ♂♀ (20–85) | HOMA-IR | > 75th vs. BDL |
OR = 8.70 (2.29; 33.10) |
OR = 5.40 (1.28; 22.76) |
||
| Lee et al.27 | ♂♀ (≥ 20) | FBG | > 75th vs. BDL |
OR = 3.1 (0.80; 11.90) |
OR = 7.00 (0.81; 60.42) |
||
| Everett et al.34 | ♂♀ (≥ 20) | HbA1c |
≥ 14.5 vs. < 14.5 (ng/g lipid) |
OR = 1.28 (0.88; 1.87) |
OR = 1.30 (0.88; 1.9) |
OR = 1.45 (1.04; 2.01) |
|
| Lee et al.28 | (20–36) | FGB. Med | Q4 vs Q1 (pg/g lipid) |
OR = 1.40 (0.47; 4.15) |
OR = 2.00 (0.59; 6.78) |
||
| Park et al.50 | ♂♀ w ms (56.5 ± 6.9)* | HOMA-IR | log ng/g lipid |
r = 0.08 (p > 0.05) |
r = 0.06 (p > 0.05) |
r = 0.20 (p > 0.05) |
|
| Park et al.50 | ♂♀ w/o ms (56.5 ± 6.9)* | HOMA-IR | log ng/g lipid |
r = 0.25 (p > 0.05) |
r = 0.20 (p > 0.05) |
r = 0.32 (p < 0.05) |
|
| Patel et al.35 | ♂♀ † | FBG | Per SD (log ng/g) |
OR = 1.70 (1.30; 2.10) |
|||
| Lee et al.30 | ♂♀ (≥ 70) | FBG. Med |
FBG ≥ 112 mg/dL or medication |
OR = 1.80 (0.49; 6.64) |
|||
| Son. et al.49 | ♂♀ † | FBG. Med |
T3 vs. T1 (ng/g lipids) |
OR = 26.00 (1.30; 518.87) |
OR = 8.10 (1.21; 54.08) |
OR = 3.10 (0.80; 12.06) |
|
| Airaksinen et al.32 | ♂♀ (62)* | FBG. Med. OGTT | ≥ 90th (19.0–76.0) vs. < 10th (0.73–6.3) (ng/g lipids) |
OR = 2.08 (1.18; 3.86) |
OR = 2.24 (1.25; 4.02) |
||
| Starling et al.48 | ♀ (17–88) | Self-reported | Exposed vs. Non-exposed |
OR = 1.48 (0.92; 2.37) |
OR = 0.95 (1.01; 1.34) |
||
| Rylander et al.36 | ♀ (30–70) | Self-reported |
Q4 vs. Q1 (ng/g lipids) |
OR = 7.22 (1.6; 32.58) |
OR = 6.56 (1.57; 27.45) |
||
| Eden et al.42 | ♂♀ (18–65) | Self-reported. Medical records |
Present vs. Absent (ng/g lipids) |
OR = 1.48 (0.88; 2.49) | OR = 2.25 (1.18; 4.29) | ||
| Zong et al.43 | ♀ † | Self-reported. Med | T3 vs T1 |
OR = 2.42 (0.51; 9.86) |
OR = 4.44 (1.08; 18.20) |
||
| Grice et al.38 | ♂♀ † | OGTT | (ng/g wet weight) |
OR = 0.85 (0.56; 1.27) |
OR = 1.06 (0.68; 1.64) |
||
| Han et al.46 | ♂♀ | FBG. Med | T3 vs T1 (ng/g lipids) | OR = 6.29 (3.20; 12.36) | |||
| Meta-analysis |
OR = 1.96 (1.19; 3.23) |
OR = 2.43 (1.64. 3.62) |
OR = 1.88 (1.42; 2.49) |
– | |||
β, Beta coefficient; OR, Odds Ratio; r, Pearson correlation; * Mean; †, Without information; w/ ms, whith metabolic syndrome; w/o ms, without metabolic syndrome; FBG, fasting blood glucose; NFBG, nonfasting blood glucose; HOMA-IR, Homeostatic model assessment—insulin resistance; Hb1A1c, hemoglobin A1c; OGTT, glucose tolerance test; Med, Medication; italic values represents studies included in meta-analysis.